RE:RE:RE:RE:RE:RE:RE:RE:Biotech industry readies for " Pharma M&A Spree" Some bigger deals have been completed this year but none were instances in which a pharma group was buying a biotech to get hold of promising drugs.
A tough antitrust environment under Lina Khan’s Federal Trade Commission as well as the political uncertainty of an election year has also slowed deal activity. But the election of Donald Trump could usher in the return of bigger healthcare tie-ups.
“Trump coming to power is generating cautious optimism for increased deal flow and investments in the biopharma sector” said Zahid Moneer, a senior managing director of healthcare at BNP Paribas. ‘There’s a cautious buzz around that in January you will see a significant rebound in activity.”
Siddhart Nahata, global head of healthcare investment banking at Morgan Stanley, said: “Bolt-ons are business as usual — large-cap [pharma groups] have had to keep doing bolt-ons to supplement their internal R&D efforts. There’s no way around that. ... in terms of M&A . . . I do certainly expect 2025 to be a more active year.”